Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrillation: a post-marketing surveillance study.
about
Real-world Data and Recommended Dosage of Non-vitamin K Oral Anticoagulants for Korean Patients.Anticoagulation in atrial fibrillation : Current evidence and guideline recommendations.Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach.[Oral anticoagulation and platelet inhibition after atrial appendage occlusion].Oral Anticoagulation in Chronic Kidney Disease and Atrial Fibrillation.Rivaroxaban does not influence hemorrhagic transformation in a diabetes ischemic stroke and endovascular thrombectomy model.
P2860
Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrillation: a post-marketing surveillance study.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Comparative risk of major blee ...... -marketing surveillance study.
@en
type
label
Comparative risk of major blee ...... -marketing surveillance study.
@en
prefLabel
Comparative risk of major blee ...... -marketing surveillance study.
@en
P2093
P2860
P1476
Comparative risk of major blee ...... -marketing surveillance study.
@en
P2093
Edin Basic
Michael Nabauer
Stefan H Hohnloser
P2860
P2888
P304
P356
10.1007/S00392-017-1098-X
P577
2017-03-14T00:00:00Z